|Speaker:||Dr. Graeme K. Frith|
|Title:||The Commercialisation of Silicon Nanowire (SiNW) Chip Detection Devices.|
|Primary Industry:||Defence, BioPharma QA/QC, Environment & Food Safety Testing|
|Executive Summary:||bioDiagnostix possesses a commercially-scaleable Silicon Nanowire (SiNW) chip-based detection platform technology. We will bring the patented technology to market using our highly-experienced management and commercialisation team. The chips are manufactured using standard CMOS technologies to high standard, large volume and competitive cost. They can be formatted to incorporate upto 240 SiNW’s (permitting multiplexing), easily derivatized to attach ligands (e.g. antibodies, oligonucleotides), and can integrate real-time reporting capabilities (e.g. RFID). This approach facilitates assay migration and consolidation onto the chip format. The technology has been used in several Proof of Adoption (PoA) studies.
Functionalised SiNW’s act as highly sensitive (10 fMol) lab-on-a-chip devices to rapidly detect single molecule binding interactions. These events are detected and reported as simple electrical resistance changes. The size of the SiNW chip facilitates the design of small, portable, low-energy devices. These devices are suitable for multiple end-user requirements including use in Point-of Care, Mass-screening and Stand-Off applications. We are targeting the Biodefence, Medical diagnostics, BioPharma, Environmental and Food testing markets using a 3-tiered business model and are currently in negotiations with several interested parties. We require a $6M investment.